SELUTION Sirolimus-eluting Balloon Registry Launched for Coronary Artery Disease
The Fundación EPIC has initiated a post-market registry to evaluate the SELUTION Sirolimus-eluting Balloon in real-world patients with coronary artery disease, focusing on effectiveness and safety over 12 months.
Phase III
coronary artery disease market
Status
Initiated
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Strategic implication
The outcomes of this registry may influence competitive positioning for the SELUTION device in the coronary intervention market, impacting future clinical adoption and potential market share against other balloon technologies.
Why it matters
The launch of the SELUTION Sirolimus-eluting Balloon registry by Fundación EPIC is a critical development that directly addresses the uncertainty surrounding the device's real-world effectiveness and safety in treating coronary artery disease.
Recommended action
Humanexa recommends Monitor: Humanexa advises monitoring the outcomes of the SELUTION registry closely, as the data collected over the next 12 months will provide valuable insights into the device's performance in a real-world setting. This information is crucial for understanding its competitive position in the market and may influence strategic decisions regarding future investments or partnerships in the cardiology space.
Analysis
Monitor the results of the primary endpoint at 12 months, including rates of major adverse cardiovascular events, which could affect market dynamics.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.